EI
ANTH

EAM Investors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

EAM Investors’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-18,812
Closed -$917K – 387
2015
Q3 		$917K Buy
18,812
+128
+0.7% +$8.94K 0.15% 271
2015
Q2 		$1.29M Buy
+18,684
New +$865K 0.15% 258

Other funds holding ANTH

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

EAM Investors's ANTH Position: Q4 2015 in Review

EAM Investors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2015, closing a stake of 18,812 shares — an estimated $917K sold.

EAM Investors first reported a position in ANTH in Q2 2015 and held it in 2 quarters. The position peaked at $1.29M in Q2 2015. 86 funds tracked by Wall St. Rank hold ANTH as of Q4 2015.

  • EAM Investors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • EAM Investors sold 18,812 Anthera Pharmaceuticals, Inc. shares in Q4 2015, an estimated $917K.
  • EAM Investors first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2015 and held it in 2 quarters.
  • EAM Investors's Anthera Pharmaceuticals, Inc. position peaked at $1.29M in Q2 2015.
  • 86 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2015.

Based on EAM Investors's 13F filing for Q4 2015, filed 5 Feb 2016.